Company news
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) news
Harmony Biosciences Holdings, Inc. news releases on 6ix. Latest, May 2, 2023: Harmony Biosciences Reports First Quarter 2023 Financial Results and Business…
Press releases — page 3
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
May 1, 2023
HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER
April 23, 2023
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023
April 19, 2023
HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
March 28, 2023
HARMONY BIOSCIENCES CONTINUES COMMUNITY COMMITMENT IN 2023 WITH PATIENTS AT THE HEART AND PROGRESS AT THE HEART NONPROFIT FUNDING PROGRAMS
February 27, 2023
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 20, 2023
HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FIFTH CONSECUTIVE YEAR
February 16, 2023
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023
February 6, 2023
HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN
January 5, 2023
HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
December 21, 2022
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE
November 8, 2022
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
October 31, 2022
HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME
October 31, 2022
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022
October 17, 2022
HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS
September 21, 2022
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 1, 2022
HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS
July 18, 2022
HARMONY BIOSCIENCES PRESENTS POST-HOC ANALYSIS OF WAKIX® (PITOLISANT) PIVOTAL DATA IN ADULTS WITH HIGH BURDEN OF NARCOLEPSY SYMPTOMS
June 5, 2022
Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
May 2, 2022
HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA
April 26, 2022
HARMONY BIOSCIENCES ANNOUNCES DATE OF FIRST QUARTER 2022 FINANCIAL RESULTS
April 18, 2022
HARMONY BIOSCIENCES OPENS APPLICATIONS FOR 2022 PROGRESS AT THE HEART PROGRAM
April 6, 2022
HARMONY BIOSCIENCES TO PARTICIPATE IN 21st ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
April 3, 2022
HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FOURTH CONSECUTIVE YEAR
March 30, 2022
HARMONY BIOSCIENCES ANNOUNCES APPLICATIONS OPEN MARCH 18 FOR 2022 PATIENTS AT THE HEART PROGRAM
March 16, 2022
HARMONY BIOSCIENCES TO PARTICIPATE IN TWO INVESTOR CONFERENCES IN MARCH
March 8, 2022
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
February 27, 2022
Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results
February 13, 2022
Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Harmony Biosciences to be Added to the Nasdaq Biotech Index
December 16, 2021
Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs
December 12, 2021
Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia
November 30, 2021
Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors
November 21, 2021
Harmony Biosciences To Participate In Two Investor Conferences In November
November 10, 2021
Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates
November 8, 2021
Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results
October 25, 2021
Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcolepsy Day
September 21, 2021
Harmony Biosciences To Participate In Three Investor Conferences In September
September 1, 2021
Harmony Biosciences Announces Inclusion Of WAKIX® (pitolisant) In American Academy Of Sleep Medicine's Updated Clinical Practice Guideline
September 1, 2021
Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates
August 9, 2021
Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration
August 9, 2021
Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases
August 8, 2021
John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 Greater Philadelphia Award Winner
July 28, 2021
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
July 26, 2021
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
June 28, 2021
/C O R R E C T I O N -- Harmony Biosciences/
June 9, 2021
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9
June 8, 2021
Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
June 6, 2021
Harmony Biosciences to Participate in Three Investor Conferences in June
May 25, 2021
John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors
May 17, 2021